Literature DB >> 12437840

Survival in second primary malignancies of patients with head and neck cancer.

Ercole Di Martino1, Bernd Sellhaus, Ralf Hausmann, Ralf Minkenberg, Melanie Lohmann, Martin W Esthofen.   

Abstract

Second primary tumours occur frequently in patients with a history of head and neck malignancies. Delays in making an early and correct diagnosis can seriously affect the therapy management and survival. This was a retrospective study of 120 patients with a history of head and neck cancer, presenting with a second primary tumour. Current follow-up strategies and the use of routine sonographic imaging of the head and neck regions were evaluated, and the impact that tumour chronology, the tumour site and the various treatment modalities have on the survival were assessed. Forty-two per cent of patients developed a metachronous second malignancy more than five years after diagnosis of the index tumour. The accuracy of colour-duplex sonography in detection of second primaries in the head and neck was 82.3 per cent. First and second primary tumours located in the larynx were observed to have the highest five-year survival rate. Patients who developed metachronous tumours had a five-year survival rate of 68.9 per cent for the index tumours, and a 26 per cent five-year survival rate with the occurrence of a second neoplasm. With synchronous tumours a mean survival time of 18 months and a five-year survival rate of 11.9 per cent was found (p < 0.0001). Where clinically appropriate an aggressive treatment strategy was employed and yielded the most favourable results with a five-year survival rate of 66.8 per cent and 35.9 per cent for index tumours and second primary malignancies, respectively. Since more than 40 per cent of the metachronous second primaries in patients with a history of head and neck malignancy occur beyond the five-year follow-up period, an extended protocol with individually adjusted close monitoring of high-risk patients seems appropriate. Colour-duplex sonography is a valuable screening investigation for the early detection of second primary tumours. The treatment of a second primary is often less successful than for the same malignancy occurring primarily. The prognosis of synchronous tumours is significantly lower when compared to malignancies of a metachronous nature, despite some encouraging individual results. Only the early implementation of aggressive treatment methods for second primaries is successful in terms of survival.

Entities:  

Mesh:

Year:  2002        PMID: 12437840     DOI: 10.1258/00222150260293664

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  24 in total

1.  Simultaneous Triple Primary Head and Neck Malignancies: A Rare Case Report.

Authors:  Ningombam Jiten Singh; Nishikanta Tripathy; Paromita Roy; Kapila Manikantan; Pattatheyil Arun
Journal:  Head Neck Pathol       Date:  2015-10-17

Review 2.  European Laryngological Society: ELS recommendations for the follow-up of patients treated for laryngeal cancer.

Authors:  Ricard Simo; Patrick Bradley; Dominique Chevalier; Frederik Dikkers; Hans Eckel; Nayla Matar; Giorgio Peretti; Cesare Piazza; Mark Remacle; Miquel Quer
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-09       Impact factor: 2.503

Review 3.  Second primary tumors in patients with head and neck cancer.

Authors:  Antonio Vitor Martins Priante; Emanuel Celice Castilho; Luiz Paulo Kowalski
Journal:  Curr Oncol Rep       Date:  2011-04       Impact factor: 5.075

4.  A Synchronous undifferentiated nasopharyngeal carcinoma and infiltrating ductal carcinoma of the breast successfully treated with induction chemotherapy followed by local control of both tumours: a case report.

Authors:  Mohamed Mesmoudi; Tarik Mahfoud; Nabil Ismaili; Khadija Rami; Meryem Kamouni; Laila Jroundi; Hassan Errihani
Journal:  BMC Ear Nose Throat Disord       Date:  2011-06-09

5.  Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers.

Authors:  Brandon W Peck; Kristina R Dahlstrom; Samuel J Gan; Wes Caywood; Guojun Li; Qingyi Wei; Mark E Zafereo; Erich M Sturgis
Journal:  Head Neck       Date:  2012-06-19       Impact factor: 3.147

Review 6.  Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis.

Authors:  Elisabeth Rudolph; Gerhard Dyckhoff; Heiko Becher; Andreas Dietz; Heribert Ramroth
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-10-19       Impact factor: 2.503

Review 7.  A genetic view of laryngeal cancer heterogeneity.

Authors:  María José de Miguel-Luken; Manuel Chaves-Conde; Amancio Carnero
Journal:  Cell Cycle       Date:  2016-03-03       Impact factor: 4.534

8.  Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck.

Authors:  Lei Jin; Erich M Sturgis; Yang Zhang; Zhigang Huang; Peng Wei; Wei Guo; Zhongqiu Wang; Qingyi Wei; Xicheng Song; Guojun Li
Journal:  Carcinogenesis       Date:  2013-03-18       Impact factor: 4.944

9.  Genome damage in oropharyngeal cancer patients treated by radiotherapy.

Authors:  Marija Gamulin; Nevenka Kopjar; Mislav Grgić; Snjezana Ramić; Vesna Bisof; Vera Garaj-Vrhovac
Journal:  Croat Med J       Date:  2008-08       Impact factor: 1.351

10.  Helical tomotherapy with simultaneous integrated boost dose painting for the treatment of synchronous primary cancers involving the head and neck.

Authors:  A M Chen; M E Daly; J Cui; H O Wooten; D G Farwell; J A Purdy
Journal:  Br J Radiol       Date:  2014-06-02       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.